arrow
D

Dana Horáková

Charles University
H指数:49
被引数:8,795

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

How patients with neuromyelitis optica spectrum disease accumulate disability

视神经脊髓炎谱系疾病患者如何累积残疾

2026-10-080
PRE
Causal effects of multiple sclerosis therapies in left-truncated registry data

多发性硬化疗法在左截断登记数据中的因果效应

2026-07-210
PRE
Adherence to risk minimization measures for alemtuzumab use in multiple sclerosis: a drug utilization study in four European countries

在四国欧洲国家进行的阿仑单抗治疗多发性硬化风险最小化措施依从性研究

2026-05-210
PRE
Disease course after pregnancy in women with progressive multiple sclerosis symptoms

妊娠后进展性多发性硬化症状女性的疾病病程

2025-09-200
OA
Real-World Laboratory Analysis of Molecular Biomarkers in Multiple Sclerosis Centers in Central-Eastern European Countries Covering 107 Million Inhabitants

中欧国家多发性硬化中心针对覆盖1.07亿人口的真实世界实验室分析:分子生物标志物研究

2025-08-270
PRE
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women’s Health Registry (2020–2024)

四年之后:MSBase妊娠、新生儿结局及女性健康登记册(2020–2024)中报告的妊娠与分娩结局

2025-07-070
PRE
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis

复发缓解型多发性硬化中与复发活动无关的进展标准化定义(PIRA)

2025-06-010
PRE
Personalized treatment decision algorithms for the clinical application of serum neurofilament light chain in multiple sclerosis: A modified Delphi Study

基于血清神经丝轻链在多发性硬化临床应用中的个性化治疗决策算法:一项改良德尔菲研究

2025-04-280
PRE
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network

原发性进行性MS患者亚类的疾病改善治疗和残疾进展: 来自大MS数据网络的结果

2024-12-060
OAAI
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies
2024-11-012
OAAI
A future of AI-driven personalized care for people with multiple sclerosis

人工智能驱动的多发性硬化症患者个性化护理的未来

2024-08-191
OAAI
Microstructural characterization of multiple sclerosis lesion phenotypes using multiparametric longitudinal analysis

利用多参数纵向分析对多发性硬化病灶表型进行微观结构表征

2024-07-130
OAAI
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis A Registry-Based Study
2024-04-094
OAAI
Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60
2024-03-074
PRE
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry

使用非随机真实世界证据模拟复发缓解型多发性硬化症的随机临床试验: 使用MSBase注册表数据的应用程序

2024-01-190
PRE